PF 07899895
Alternative Names: PF-07899895Latest Information Update: 08 Dec 2023
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Protein-serine-threonine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ulcerative colitis
Most Recent Events
- 18 Nov 2023 Pfizer plans a phase I trial (In volunteers) in Belgium (PO) in November 2023 (NCT06137729)
- 17 Nov 2023 Phase-I clinical trials in Ulcerative colitis (In volunteers) in Belgium (PO, Immediate release) (NCT06137729)
- 17 Nov 2023 Unspecified in USA (PO), before November 2023